Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

StrykerSYK saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 64 to 71. Please watch the video at Investors.com - Stock Market Exposure: How To Make ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Stryker has been in a holding pattern, posting a small return of 1.1% while floating around $376.76. Is now the time to buy ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $3,978.93 today based on a ...

Looking at stock returns, SYK, with 0% returns in the last twelve months, has fared better than ISRG stock, down 20%, and the broader S&P500 index, down 9%.